Department of Urology, Dongguk University College of Medicine, Gyeongju, Korea
Copyright © 2021 Yeungnam University College of Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of interest
No potential conflict of interest relevant to this article was reported.
Variable |
Incontinence rate |
|||
---|---|---|---|---|
1 Mo | 3 Mo | 6 Mo | 12 Mo | |
Group | ||||
Non-UL group (n=23) | 12 (52.2) | 11 (47.8) | 4 (17.4) | 1 (4.3) |
UL group (n=30) | 25 (83.3) | 23 (76.7) | 7 (23.3) | 3 (10.0) |
p-value | 0.014 | 0.030 | 0.597 | 0.440 |
Degree of leakagea) | ||||
Mild (n=6) | 4 (66.7) | 4 (66.7) | 3 (50.0) | 0 |
Moderate (n=12) | 11 (91.7) | 10 (83.3) | 1 (8.3) | 1 (8.3) |
Severe (n=12) | 10 (83.3) | 9 (75.0) | 3 (25.0) | 2 (16.7) |
p-valueb) | 0.066 | 0.157 | 0.209 | 0.519 |
Characteristic | UL group (n=30) | Non-UL group (n=23) | p-value |
---|---|---|---|
Age (yr) | 69.1±4.8 | 68.4±5.9 | 0.649 |
Body mass index (kg/m2) | 25.1±2.9 | 23.6±2.6 | 0.059 |
Prostate volume (mL) | 41.0±21.5 | 39.0±14.4 | 0.709 |
Preoperative PSA (ng/mL) | 10.4±9.0 | 9.8±9.2 | 0.830 |
Mean operative time (min) | 218.6±33.5 | 193.1±43.8 | 0.088 |
Estimated blood loss (mL) | 284.7±129.8 | 268.2±143.0 | 0.664 |
Catheterization (day) | 20.6±7.5 | 9.7±0.9 | 0.001 |
Pathologic stage | 0.152 | ||
T2 | 15 (50.0) | 7 (30.4) | |
T3 | 15 (50.0) | 16 (69.6) | |
Pathologic Gleason score | 0.615 | ||
6 | 0 | 2 (8.7) | |
7 | 14 (46.7) | 12 (52.2) | |
8 | 7 (23.3) | 2 (8.7) | |
9 | 9 (30.0) | 6 (26.1) | |
10 | 0 | 1 (4.3) | |
Positive surgical margin | 8 (26.7) | 8 (34.8) | 0.524 |
Variable | Incontinence rate |
|||
---|---|---|---|---|
1 Mo | 3 Mo | 6 Mo | 12 Mo | |
Group | ||||
Non-UL group (n=23) | 12 (52.2) | 11 (47.8) | 4 (17.4) | 1 (4.3) |
UL group (n=30) | 25 (83.3) | 23 (76.7) | 7 (23.3) | 3 (10.0) |
p-value | 0.014 | 0.030 | 0.597 | 0.440 |
Degree of leakage |
||||
Mild (n=6) | 4 (66.7) | 4 (66.7) | 3 (50.0) | 0 |
Moderate (n=12) | 11 (91.7) | 10 (83.3) | 1 (8.3) | 1 (8.3) |
Severe (n=12) | 10 (83.3) | 9 (75.0) | 3 (25.0) | 2 (16.7) |
p-value |
0.066 | 0.157 | 0.209 | 0.519 |
Variable | OR (95% CI) | p-value |
---|---|---|
Age | 1.044 (0.925–1.179) | 0.483 |
Body mass index | 1.250 (0.955–1.637) | 0.105 |
Prostate-specific antigen | 1.019 (0.939–1.105) | 0.655 |
Pathologic T stage | 1.204 (0.293–4.945) | 0.796 |
Gleason score | 1.160 (0.585–2.298) | 0.671 |
Prostate size | 1.006 (0.970–1.043) | 0.754 |
Duration of catheterization | 1.317 (0.733–2.366) | 0.357 |
Degree of leakage | 1.213 (0.105–8.551) | 0.111 |
Urinary leakage | 3.301 (0.973–11.207) | 0.045 |
Variable | OR | 95% CI | p-value |
---|---|---|---|
Age | 1.080 | 0.908–1.284 | 0.386 |
Body mass index | 1.098 | 0.843–1.431 | 0.486 |
PSA | 0.965 | 0.868–1.072 | 0.506 |
Pathologic T stage | 5.730 | 0.753–43.626 | 0.092 |
Gleason score | 0.409 | 0.133–1.252 | 0.117 |
Prostate size | 1.018 | 0.981–1.056 | 0.344 |
Duration of catheterization | 1.211 | 0.937–1.565 | 0.143 |
Degree of leakage | 0.082 | 0.003–2.577 | 0.155 |
Urinary leakage | 0.107 | 0.008–1.425 | 0.091 |
Variable | OR | 95% CI | p-value |
---|---|---|---|
Age | 1.015 | 0.702–1.466 | 0.939 |
Body mass index | 2.111 | 0.832–5.359 | 0.116 |
PSA | 1.101 | 0.877–1.381 | 0.407 |
Pathologic T stage | 2.985 | 0.094–94.440 | 0.535 |
Gleason score | 2.743 | 0.267–28.200 | 0.396 |
Prostate size | 0.862 | 0.636–1.168 | 0.339 |
Duration of catheterization | 0.696 | 0.293–1.652 | 0.412 |
Degree of leakage | 570.906 | 0.003–7.853 | 0.178 |
Urinary leakage | 600.972 | 0.042–2.647 | 0.177 |
Values are presented as mean±standard deviation or number (%). PSA, prostate-specific antigen.
Values are presented as number (%). Mild, leakage occurred after injecting 200 mL normal saline (NS); moderate, leakage occurred after injecting 100 mL NS; severe, leakage occurred before injecting 100 mL NS. Non-UL group, Mild, Moderate and Severe UL group were analyzed by chi-square test.
OR, odds ratio; CI, confidence interval.
PPUI, postprostatectomy urinary incontinence; OR, odds ratio; CI, confidence interval; PSA, prostate specific antigen.
PPUI, postprostatectomy urinary incontinence; OR, odds ratio; CI, confidence interval; PSA, prostate specific antigen.